• Explore /
  • Poster
  • / Identification of patients with ovarian cancer who are experiencing the highest benefit from bevacizumab in first-line setting based on their tumor intrinsic chemosensitivity (KELIM): GOG-0218 validation study.

Identification of patients with ovarian cancer who are experiencing the highest benefit from bevacizumab in first-line setting based on their tumor intrinsic chemosensitivity (KELIM): GOG-0218 validation study.

Abstract Video & Slides Poster

Authors

null

Benoit You

Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), Lyon, France

Benoit You , Christopher Purdy , Elizabeth M. Swisher , Michael A. Bookman , Gini F. Fleming , Robert L. Coleman , Leslie M. Randall , Krishnansu Sujata Tewari , Bradley J. Monk , Robert S. Mannel , Joan L. Walker , Fabio Cappuccini , Larry J. Copeland , Mahvish Muzaffar , David Gardner Mutch , Andrea Elisabeth Wahner Hendrickson , Lainie P. Martin , Olivier Colomban , Robert Allen Burger

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 5553)

DOI

10.1200/JCO.2022.40.16_suppl.5553

Abstract #

5553

Poster Bd #

432

Abstract Disclosures

Similar Posters

First Author: Robert Allen Burger

First Author: Kristina Lindemann

First Author: Anne-Claire Hardy-Bessard

First Author: Benoit You